Download PDF
Thromb Haemost 2008; 100(01): 151-153
DOI: 10.1160/TH08-02-0089
Case Report
Schattauer GmbH

Treatment of acquired thrombotic thrombocytopenic purpura (TTP) with plasma infusion plus rituximab

Stefan Hagel   *
1   Department of Nephrology and Hypertension, University Hospital Erlangen, University of Erlangen-Nuremberg, Germany
,
Jonathan Jantsch   *
1   Department of Nephrology and Hypertension, University Hospital Erlangen, University of Erlangen-Nuremberg, Germany
2   Interdisciplinary Center for Clinical Research (IZKF), University of Erlangen-Nuremberg, Germany
,
Ulrich Budde
3   Aesculabor Hamburg, Hamburg, Germany
,
Joachim R. Kalden
4   Department of Internal Medicine 3, University Hospital Erlangen, University of Erlangen-Nuremberg, Germany
,
Kai-Uwe Eckardt
1   Department of Nephrology and Hypertension, University Hospital Erlangen, University of Erlangen-Nuremberg, Germany
,
Roland Veelken
1   Department of Nephrology and Hypertension, University Hospital Erlangen, University of Erlangen-Nuremberg, Germany
› Author Affiliations
Further Information

Publication History

Received 15 February 2008

Accepted after major revision 27 April 2008

Publication Date:
22 November 2017 (online)

    Permissions and Reprints

 

* Both authors contributed equally.


 

  • References

  • 1 Levy GG, Motto DG, Ginsburg D. ADAMTS13 turns 3. Blood 2005; 106: 11-17.
    CrossrefPubMedGoogle Scholar
  • 2 Rizvi MA, Vesely SK, George JN. et al. Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic-uremic syndrome. Transfusion 2000; 40: 896-901.
    CrossrefPubMedGoogle Scholar
  • 3 Rock GA, Shumak KH, Buskard NA. et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. CanadianApheresis Study Group. N Engl J Med 1991; 325: 393-397.
    CrossrefPubMedGoogle Scholar
  • 4 Tsai HM, Raoufi M, Zhou W. et al. ADAMTS13-binding IgG are present in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 2006; 95: 886-892.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Cataland SR, Wu HM. Immunotherapy for thrombotic thrombocytopenic purpura. Curr Opin Hematol 2005; 12: 359-363.
    CrossrefPubMedGoogle Scholar
  • 6 Heidel F, Lipka DB, von Auer C. et al. Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia. Thromb Haemost 2007; 97: 228-233.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 George JN, Woodson RD, Kiss JE. et al. Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders. J Clin Apher 2006; 21: 49-56.
    CrossrefPubMedGoogle Scholar
  • 8 Franchini M, Veneri D, Lippi G. et al. The efficacy of rituximab in the treatment of inhibitor-associated he-mostatic disorders. Thromb Haemost 2006; 96: 119-125.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Scully M, Cohen H, Cavenagh J. et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol 2007; 136: 451-461.
    CrossrefPubMedGoogle Scholar
  • 10 Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 2006; 06: 394-403.
    CrossrefPubMedGoogle Scholar
  • 11 Ferrari S, Scheiflinger F, Rieger M. et al. Prognostic value of anti-ADAMTS 13 antibody features (Ig iso-type, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectableADAMTS 13 activity. Blood 2007; 109: 2815-2822.
    PubMedGoogle Scholar
  • 12 Cserti CM, Landaw S, Uhl L. Do infections provoke exacerbations and relapses of thrombotic thrombocytopenic purpura?. J Clin Apher 2007; 22: 21-25.
    CrossrefPubMedGoogle Scholar
  • 13 Hauser SL, Waubant E, Arnold DL. et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676-688.
    CrossrefPubMedGoogle Scholar
  • 14 McFarland HF. The B cell--old player, new position on the team. N Engl J Med 2008; 358: 664-665.
    CrossrefPubMedGoogle Scholar
  • 15 Stasi R, Cooper N, Del Poeta G. et al. Analysis of regulatory T cell changes in patients with idiopathic thrombocytopenic purpura receiving B-cell depleting therapy with rituximab. Blood. 2008 prepub online doi:10.1182/blood-2007-12-129262..
    PubMedGoogle Scholar
  • 16 George JN. Clinical practice. Thrombotic thrombocytopenic purpura. N Engl J Med 2006; 354: 1927-1935.
    CrossrefPubMedGoogle Scholar